Table 1: Baseline characteristics of study patients.
|
|
Policosanol (n = 200) |
Placebo (n = 200) |
Total (n = 400) |
||||
|
Age (years) (X ± DE) |
46.3 ± 9.3 |
46.3 ± 8.5 |
46.3 ± 9.9 |
||||
|
Body mass index (kg/m2) (X ± SD) |
26.6 ± 4.6 |
26.6 ± 4.5 |
26.6 ± 4.6 |
||||
|
Gender |
n |
% |
n |
% |
n |
% |
|
|
Women |
148 |
74.0 |
148 |
74.0 |
296 |
74.0 |
|
|
Men |
52 |
26.0 |
52 |
26.0 |
104 |
26.0 |
|
|
Pre-hypertensive patients |
100 |
50.0 |
100 |
50.0 |
200 |
50.0 |
|
|
Patients with grade I hypertension |
100 |
50.0 |
100 |
50.0 |
200 |
50.0 |
|
|
Personal history |
|
|
|
|
|
|
|
|
Overweight (kg/m2 ≥ 25, < 30) |
74 |
37.0 |
74 |
37.0 |
148 |
37.0 |
|
|
Menopause |
53 |
26.5 |
58 |
29.0 |
111 |
27.8 |
|
|
Sedentary life |
42 |
21.0 |
51 |
25.5 |
93 |
23.3 |
|
|
Smoking |
34 |
17.0 |
39 |
19.5 |
73 |
18.3 |
|
|
Obesity (kg/m2 ≥ 30) |
30 |
15.0 |
32 |
16.0 |
68 |
15.5 |
|
|
Salt rich diet |
24 |
12.0 |
24 |
12.0 |
48 |
12.0 |
|
|
Dyslipidaemia |
26 |
13.0 |
21 |
10.5 |
47 |
11.8 |
|
|
Diabetes mellitus |
10 |
5.0 |
7 |
3.5 |
17 |
4.3 |
|
|
Family history |
|
||||||
|
Hypertension |
164 |
82 |
161 |
80.5 |
325 |
81.3 |
|
|
Cardiovascular disease |
67 |
33.5 |
71 |
35.5 |
138 |
34.5 |
|
|
Concomitant drug therapy |
|
|
|
||||
|
Patients consuming concomitant drug |
50 |
25 |
48 |
24 |
98 |
24.5 |
|
|
Antihistamines |
8 |
4.0 |
6 |
3.0 |
14 |
3.5 |
|
|
Oral hypoglycemic |
6 |
3.0 |
4 |
2.0 |
10 |
2.5 |
|
|
Paracetamol/NSAIDs* |
4 |
2.0 |
4 |
2.0 |
8 |
2.0 |
|
X mean, SD standard deviation, NSAIDs non-steroidal anti-inflammatory drugs
The table includes those concomitant drugs consumed ≥ 4 participants
All comparisons were not significant (ANOVA, χ2 test)